ADMA Biologics, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2025: USD 7.90 M

ADMA Biologics, Inc. Depreciation And Amortization is USD 7.90 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -6.10% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.
  • ADMA Biologics, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 8.41 M, a 11.34% change year over year.
  • ADMA Biologics, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 7.56 M, a 29.03% change year over year.
  • ADMA Biologics, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 5.86 M, a 33.61% change year over year.
  • ADMA Biologics, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 4.38 M, a 35.21% change year over year.
Key Data
Date Depreciation And Amortization Dividends Paid Common Stock Issued Common Stock Repurchased